EP1390057A4 - Novel antibodies that bind to antigenic polypeptides, nucleic acids encoding the antigens, and method of use - Google Patents

Novel antibodies that bind to antigenic polypeptides, nucleic acids encoding the antigens, and method of use

Info

Publication number
EP1390057A4
EP1390057A4 EP02763906A EP02763906A EP1390057A4 EP 1390057 A4 EP1390057 A4 EP 1390057A4 EP 02763906 A EP02763906 A EP 02763906A EP 02763906 A EP02763906 A EP 02763906A EP 1390057 A4 EP1390057 A4 EP 1390057A4
Authority
EP
European Patent Office
Prior art keywords
bind
nucleic acids
antigens
acids encoding
antigenic polypeptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02763906A
Other languages
German (de)
French (fr)
Other versions
EP1390057A2 (en
Inventor
Muralidhara Padigaru
Suresh G Shenoy
Ramesh Kekuda
Luca Rastelli
Peter S Mezes
Glennda Smithson
Xiaojia Guo
Valerie Gerlach
Stacie J Casman
Ferenc L Boldog
Li Li
Bryan D Zerhusen
Velizar T Tchernev
Esha A Gangolli
Corine A M Vernet
Kimberly A Spytek
Uriel M Malyankar
Meera Patturajan
Charles E Miller
Raymond J Taupier Jr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CuraGen Corp
Original Assignee
CuraGen Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/114,153 external-priority patent/US20030185815A1/en
Application filed by CuraGen Corp filed Critical CuraGen Corp
Publication of EP1390057A2 publication Critical patent/EP1390057A2/en
Publication of EP1390057A4 publication Critical patent/EP1390057A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/01—Hexosyltransferases (2.4.1)
    • C12Y204/0115—N-Acetyllactosaminide beta-1,6-N-acetylglucosaminyl-transferase (2.4.1.150)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Disclosed herein are nucleic acid sequences that encode polypeptides. Also disclosed are antibodies, which immunospecifically-bind to the polypeptide, as well as derivatives, variants, mutants, or fragments of the aforementioned polypeptide, polynucleotide, or antibody. The invention further discloses therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of disorders involving any one of these novel human nucleic acids, polypeptides, or antibodies, or fragments thereof.
EP02763906A 2001-04-03 2002-04-03 Novel antibodies that bind to antigenic polypeptides, nucleic acids encoding the antigens, and method of use Withdrawn EP1390057A4 (en)

Applications Claiming Priority (51)

Application Number Priority Date Filing Date Title
US28108601P 2001-04-03 2001-04-03
US281086P 2001-04-03
US28190601P 2001-04-05 2001-04-05
US281906P 2001-04-05
US28202001P 2001-04-06 2001-04-06
US282020P 2001-04-06
US28293001P 2001-04-10 2001-04-10
US282930P 2001-04-10
US28351201P 2001-04-12 2001-04-12
US28344401P 2001-04-12 2001-04-12
US283444P 2001-04-12
US283512P 2001-04-12
US28371001P 2001-04-13 2001-04-13
US28367801P 2001-04-13 2001-04-13
US28365701P 2001-04-13 2001-04-13
US283710P 2001-04-13
US283678P 2001-04-13
US283657P 2001-04-13
US28423401P 2001-04-17 2001-04-17
US284234P 2001-04-17
US28532501P 2001-04-19 2001-04-19
US285325P 2001-04-19
US28538101P 2001-04-20 2001-04-20
US285381P 2001-04-20
US28606801P 2001-04-24 2001-04-24
US286068P 2001-04-24
US28629201P 2001-04-25 2001-04-25
US286292P 2001-04-25
US29669201P 2001-06-07 2001-06-07
US296692P 2001-06-07
US30088301P 2001-06-26 2001-06-26
US300883P 2001-06-26
US31100301P 2001-08-08 2001-08-08
US311003P 2001-08-08
US31197301P 2001-08-13 2001-08-13
US311973P 2001-08-13
US31290101P 2001-08-16 2001-08-16
US312901P 2001-08-16
US32228301P 2001-09-14 2001-09-14
US322283P 2001-09-14
US32744801P 2001-10-05 2001-10-05
US327448P 2001-10-05
US34573401P 2001-12-31 2001-12-31
US345734P 2001-12-31
US34575502P 2002-01-03 2002-01-03
US345755P 2002-01-03
US35439102P 2002-02-04 2002-02-04
US354391P 2002-02-04
US10/114,153 US20030185815A1 (en) 2001-04-03 2002-04-02 Novel antibodies that bind to antigenic polypeptides, nucleic acids encoding the antigens, and methods of use
PCT/US2002/010366 WO2002081625A2 (en) 2001-04-03 2002-04-03 Novel antibodies that bind to antigenic polypeptides, nucleic acids encoding the antigens, and methods of use
US114153P 2008-11-13

Publications (2)

Publication Number Publication Date
EP1390057A2 EP1390057A2 (en) 2004-02-25
EP1390057A4 true EP1390057A4 (en) 2005-10-12

Family

ID=28795516

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02763906A Withdrawn EP1390057A4 (en) 2001-04-03 2002-04-03 Novel antibodies that bind to antigenic polypeptides, nucleic acids encoding the antigens, and method of use

Country Status (3)

Country Link
EP (1) EP1390057A4 (en)
JP (1) JP2005507236A (en)
CA (1) CA2442739A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101512203B1 (en) * 2006-11-10 2015-04-15 가부시키가이샤 리부텍쿠 ANTI-HUMAN Dlk-1 ANTIBODY SHOWING ANTI-TUMOR ACTIVITY IN VIVO
EP2275537B1 (en) 2008-03-17 2014-12-24 Livtech Inc. Anti-human dlk-1 antibody having anti-tumor activity in vivo
US10752668B2 (en) * 2014-07-25 2020-08-25 Theravectys Lentiviral vectors for regulated expression of a chimeric antigen receptor molecule

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000058473A2 (en) * 1999-03-31 2000-10-05 Curagen Corporation Nucleic acids including open reading frames encoding polypeptides; 'orfx'
WO2001083744A2 (en) * 2000-05-02 2001-11-08 Merck Patent Gmbh Natrium-calcium exchanger protein

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000058473A2 (en) * 1999-03-31 2000-10-05 Curagen Corporation Nucleic acids including open reading frames encoding polypeptides; 'orfx'
WO2001083744A2 (en) * 2000-05-02 2001-11-08 Merck Patent Gmbh Natrium-calcium exchanger protein

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL [online] 20 November 1995 (1995-11-20), "Homo sapiens partial SCL8A3 gene for solute carrier family 8 (sodium/calcium exchanger), member 3 (SCL8A3), exon 2", XP002210607, retrieved from EBI accession no. EM_HUM:HSNCX22 Database accession no. HSNCX22 *
DATABASE EMBL [online] 6 June 2001 (2001-06-06), "Homo sapiens mRNA for sodium/calcium exchanger SCL8A3, alternative splice form A (SCL8A3 gene)", XP002327581, retrieved from EBI accession no. EM_PRO:AJ304852 Database accession no. AJ304852 *
DATABASE EMBL [online] 6 June 2001 (2001-06-06), "Homo sapiens mRNA for sodium/calcium exchanger, SCL8A3, alternative splice form B (SCL8A3 gene)", XP002222548, retrieved from EBI accession no. EM_PRO:HSA304853 Database accession no. HSA304853 *
DATABASE SWISSPROT [online] 1 October 2000 (2000-10-01), "Sodium/calcium exchanger 2 precursor (Na+/Ca2+-exchange protein 2).", XP002327580, retrieved from EBI Database accession no. Q9UPR5 *
EGGER M ET AL: "Regulatory function of Na-Ca exchange in the heart: milestones and outlook.", THE JOURNAL OF MEMBRANE BIOLOGY. 15 MAR 1999, vol. 168, no. 2, 15 March 1999 (1999-03-15), pages 107 - 130, XP002327588, ISSN: 0022-2631 *
IWAMOTO TAKAHIRO ET AL: "Chimeric analysis of Na+/Ca2+ exchangers NCX1 and NCX3 reveals structural domains important for differential sensitivity to external Ni2+ or Li+", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 274, no. 33, 13 August 1999 (1999-08-13), pages 23094 - 23102, XP002327579, ISSN: 0021-9258 *
KRAEV A ET AL: "The organization of the human gene NCX1 encoding the sodium-calcium exchanger", GENOMICS, ACADEMIC PRESS, SAN DIEGO, US, vol. 37, no. 1, 1996, pages 105 - 112, XP002181613, ISSN: 0888-7543 *

Also Published As

Publication number Publication date
EP1390057A2 (en) 2004-02-25
CA2442739A1 (en) 2002-10-17
JP2005507236A (en) 2005-03-17

Similar Documents

Publication Publication Date Title
WO2002014368A8 (en) Proteins and nucleic acids encoding the same
WO2002055705A3 (en) Proteins and nucleic acids encoding same
WO2002064791A3 (en) Proteins and nucleic acids encoding same
WO2002057453A3 (en) Polypetides and nucleic acids encoding same
WO2002068649A3 (en) Proteins and nucleic acids encoding same
WO2002057450A3 (en) Proteins and nucleic acids encoding same
WO2001060990A3 (en) Sphingosine kinases
WO2002029058A3 (en) Human proteins, polynucleotides encoding them and methods of using the same
WO2004015060A3 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
WO2002068652A3 (en) Nov-x proteins and nucleic acids encoding same
WO2002016599A3 (en) Proteins and nucleic acids encoding same
WO2002081625A3 (en) Novel antibodies that bind to antigenic polypeptides, nucleic acids encoding the antigens, and methods of use
WO2002029038A3 (en) Novel proteins and nucleic acids encoding same and antibodies directed against these proteins
WO2002055704A3 (en) Proteins, polynucleotides encoding them and methods of using the same
WO2002010216A3 (en) Proteins and nucleic acids encoding same
WO2002055702A3 (en) Human proteins, polynucleotides encoding them and methods of using the same
WO2002081510A3 (en) Proteins, polynucleotides encoding them and methods of using the same
WO2002099062A3 (en) Novel antibodies that bind to antigenic polypeptides, nucleic acids encoding the antigens, and methods of use
WO2002046229A3 (en) Novel proteins and nucleic acids encoding same
WO2002079398A3 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
WO2002066643A3 (en) Proteins, polynucleotides encoding them and methods of using the same
WO2001066747A3 (en) Proteins named fctrx and nucleic acids encoding same
WO2002099116A3 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
WO2003022998A3 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
WO2002090504A3 (en) Novel antibodies that bind to antigenic polypeptides, nucleic acids encoding the antigens, and methods of use

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20031031

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

RIN1 Information on inventor provided before grant (corrected)

Inventor name: MAZUR, ANN

Inventor name: STONE, DAVID J.

Inventor name: EDINGER, SHLOMIT R.

Inventor name: MACDOUGALL, JOHN R.

Inventor name: CATTERTON, ELINA

Inventor name: PEYMAN, JOHN A.

Inventor name: JU, JINGFANG

Inventor name: HEYES, MELVYN P.

Inventor name: TAUPIER, RAYMOND J., JR.

Inventor name: MILLER, CHARLES, E.

Inventor name: PATTURAJAN, MEERA

Inventor name: MALYANKAR, URIEL M.

Inventor name: SPYTEK, KIMBERLY, A.

Inventor name: VERNET, CORINE, A., M.

Inventor name: GANGOLLI, ESHA, A.

Inventor name: TCHERNEV, VELIZAR, T.

Inventor name: ZERHUSEN, BRYAN, D.

Inventor name: LI, LI

Inventor name: BOLDOG, FERENC, L.

Inventor name: CASMAN, STACIE, J.

Inventor name: GERLACH, VALERIE

Inventor name: GUO, XIAOJIA

Inventor name: SMITHSON, GLENNDA

Inventor name: MEZES, PETER, S.

Inventor name: RASTELLI, LUCA

Inventor name: KEKUDA, RAMESH

Inventor name: SHENOY, SURESH, G.

Inventor name: PADIGARU, MURALIDHARA

RTI1 Title (correction)

Free format text: NOVEL ANTIBODIES THAT BIND TO ANTIGENIC POLYPEPTIDES, NUCLEIC ACIDS ENCODING THE ANTIGENS, AND METHOD OF USE

RTI1 Title (correction)

Free format text: NOVEL ANTIBODIES THAT BIND TO ANTIGENIC POLYPEPTIDES, NUCLEIC ACIDS ENCODING THE ANTIGENS, AND METHOD OF USE

RIC1 Information provided on ipc code assigned before grant

Ipc: 7C 12N 15/12 B

Ipc: 7C 07K 14/47 A

A4 Supplementary search report drawn up and despatched

Effective date: 20050824

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20060217